acquisition

SciSparc's NeuroThera Labs acquires 54% of quantum clinical trials company CliniQuantum for $9.46M in stock plus $2.5M earn-out, closing by March 2026.

NexGel acquires regenerative biomaterial portfolio from Celularity, expecting to nearly triple 2026 revenue to $35M and achieve immediate profitability.

$VTAK completes acquisition of remaining 80.02% stake in Fly Flyte, achieving 100% ownership of FAA-certified regional aviation operator with active revenue operations.

Coatue Management exits $920M CoreWeave stake entirely over profitability concerns while boosting Netflix position to $1B+ following stock split.

Renk Group AG files routine executive transaction notification involving manager Anja Mänz-Siebje, demonstrating compliance with European securities regulations.

Renk Group AG executive Anja Mänz-Siebje completes insider stock transaction, subject to regulatory disclosure requirements.

Mowi acquires Torghatten Aqua's Northern Norway salmon business for €26 million, gaining 3.37 licenses and 4,500 GWT annual production capacity.

Allied Gold shareholders will vote March 31 on Zijin's C$44-per-share all-cash acquisition, valuing the company at C$5.5 billion with a 27% premium.

Tilray completes BrewDog Australia acquisition with brewery and bars; stock falls 3.68% despite Asia-Pacific expansion strategy.

Universal Health Services to acquire Talkspace for $5.25/share in $835M deal, expanding virtual therapy access through 6,000 licensed professionals.

La Rosa Holdings pivots to AI infrastructure through proposed all-equity acquisition of Nvidia Cloud Partner Consensus Core, targeting 2+ gigawatts of North American capacity.

Klotho Neurosciences rebrands to Greenland Mines Ltd, shifting from neuroscience to natural resources with focus on a $68 billion palladium deposit in Greenland.

Agilent acquires Biocare Medical for $950M to expand pathology and immunohistochemistry capabilities. Deal expected accretive to EPS within 12 months, closing by Q4 2026.

Woodward acquires Florida-based VRM to strengthen aerospace flow control capabilities, adding solenoid and relief valves to its portfolio. Deal closes H1 2026.

Microsoft offers better value than Netflix despite recent losses, as it capitalizes on AI infrastructure demand with proven monetization paths versus Netflix's streaming competition.

Netflix rebounds to $100/share after failed Warner Bros. Discovery deal, posting 16% revenue growth. Analysts see $150 potential amid streaming competition.

Cannabis leader $CGC has crashed 99% from $568 peak to ~$1, facing profitability challenges and dilutive acquisition amid intense competition.

Lisata Therapeutics agreed to be acquired by Kuva Labs for $5.00 per share plus up to $1.00 contingent payment, closing expected in Q2 2026.

Lisata Therapeutics agrees to be acquired by Kuva Labs for $5 per share plus up to $1 contingent payment tied to FDA approval, with close expected in Q2 2026.

Tevogen Bio ($TVGN) pursues Apozeal acquisition to bolster generics platform; stock plunges 15.41% despite initial rally, trading at 52-week lows amid strategic uncertainty.